Literature DB >> 12696117

Cellular and humoral immune responses to measles in immune adults re-immunized with measles vaccine.

Rosa Maria Wong-Chew1, Judy A Beeler, Susette Audet, José Ignacio Santos.   

Abstract

The objective of this study was to characterize the kinetics of the cellular and humoral immune responses elicited by measles vaccine given to previously immune adults. The cellular and humoral immune responses to measles were measured in seven healthy adults, before vaccination and at 1, 2, 3, and 4 weeks and 3 months after vaccination, using measles-specific T-cell proliferation and plaque reduction neutralization assays. All study subjects had detectable measles antibodies, but only six (85%) showed protective titers, defined as >1:120, before immunization. However measles-specific T-cell proliferation was not detectable before vaccination in any of the subjects. The six subjects with protective titers showed a positive stimulation index (SI) of >3.0 within the first 4 weeks after vaccination, an SI of 5 at the 4th week, and an SI of 3 at 3 months after vaccination. The subject with a low antibody titer (1:99) before vaccination developed a high SI at 3 months after vaccination. This subject was the only participant whose neutralizing antibody titers increased more than 4-fold by 3 months after vaccination. No significant increases in geometric mean titers were detected in the other six subjects during the follow-up period. These data suggest that high measles antibody titers interfere with the humoral response in subjects who receive a booster immunization, whereas the cellular response is boosted at least transiently, after revaccination. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12696117     DOI: 10.1002/jmv.10390

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  11 in total

1.  Increasing the time of exposure to aerosol measles vaccine elicits an immune response equivalent to that seen in 9-month-old Mexican children given the same dose subcutaneously.

Authors:  Rosa María Wong-Chew; Miguel Leonardo García-León; Bogart Espinosa-Torres Torrija; Brenda Hernández-Pérez; Lino E Cardiel-Marmolejo; Judy A Beeler; Susette Audet; José Ignacio Santos-Preciado
Journal:  J Infect Dis       Date:  2011-08-01       Impact factor: 5.226

2.  Immunologic significance of HLA class I genes in measles virus-specific IFN-gamma and IL-4 cytokine immune responses.

Authors:  Inna G Ovsyannikova; Jenna E Ryan; Robert A Vierkant; V Shane Pankratz; Robert M Jacobson; Gregory A Poland
Journal:  Immunogenetics       Date:  2005-12-06       Impact factor: 2.846

3.  Measles Virus Enters Breast and Colon Cancer Cell Lines through a PVRL4-Mediated Macropinocytosis Pathway.

Authors:  Sebastien Delpeut; Gary Sisson; Karen M Black; Christopher D Richardson
Journal:  J Virol       Date:  2017-04-28       Impact factor: 5.103

4.  Measles Virus Neutralizing Antibody Response, Cell-Mediated Immunity, and Immunoglobulin G Antibody Avidity Before and After Receipt of a Third Dose of Measles, Mumps, and Rubella Vaccine in Young Adults.

Authors:  Amy Parker Fiebelkorn; Laura A Coleman; Edward A Belongia; Sandra K Freeman; Daphne York; Daoling Bi; Ashwin Kulkarni; Susette Audet; Sara Mercader; Marcia McGrew; Carole J Hickman; William J Bellini; Rupak Shivakoti; Diane E Griffin; Judith Beeler
Journal:  J Infect Dis       Date:  2015-11-23       Impact factor: 5.226

5.  Evaluation of Measles Vaccine Virus as a Vector to Deliver Respiratory Syncytial Virus Fusion Protein or Epstein-Barr Virus Glycoprotein gp350.

Authors:  Hoyin Mok; Xing Cheng; Qi Xu; James R Zengel; Bandita Parhy; Jackie Zhao; C Kathy Wang; Hong Jin
Journal:  Open Virol J       Date:  2012-02-16

Review 6.  Environmental Risk Assessment of Recombinant Viral Vector Vaccines against SARS-Cov-2.

Authors:  Aline Baldo; Amaya Leunda; Nicolas Willemarck; Katia Pauwels
Journal:  Vaccines (Basel)       Date:  2021-05-03

7.  Immunogenicity of a recombinant measles-HIV-1 clade B candidate vaccine.

Authors:  Richard Stebbings; Michèle Février; Bo Li; Clarisse Lorin; Marguerite Koutsoukos; Edward Mee; Nicola Rose; Joanna Hall; Mark Page; Neil Almond; Gerald Voss; Frédéric Tangy
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

Review 8.  The tumor-associated marker, PVRL4 (nectin-4), is the epithelial receptor for morbilliviruses.

Authors:  Sebastien Delpeut; Ryan S Noyce; Christopher D Richardson
Journal:  Viruses       Date:  2014-06-02       Impact factor: 5.048

Review 9.  Chikungunya vaccines in development.

Authors:  Michael Schwameis; Nina Buchtele; Patricia Pia Wadowski; Christian Schoergenhofer; Bernd Jilma
Journal:  Hum Vaccin Immunother       Date:  2016-03-03       Impact factor: 3.452

Review 10.  Biosafety considerations for attenuated measles virus vectors used in virotherapy and vaccination.

Authors:  Aline Baldo; Evanthia Galanis; Frédéric Tangy; Philippe Herman
Journal:  Hum Vaccin Immunother       Date:  2015-12-02       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.